Home
Healthcare
Healthcare & Pharmaceuticals
Mitomycin C Market Size, Share, and Industry Report [2031]

Mitomycin C Market

Name: Growth Market Reports
Address: 500 East E Street, Ontario, 91764, USA
Telephone: +1 909 414 1393

Segments - By Type (2mg, 10 mg, 40 mg, and Others), By Application (Cancer Treatment, Ophthalmic Use, and Others), and Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

HC-5357
4.9 Rating
284 Pages

26-05-2023
63 Reviews

Author :

Raksha Sharma

Fact-checked by :

Vineet Pandey

Editor :

Vishal Golekar

Report Description

Mitomycin C Market Market Outlook:

The Global Mitomycin C Market was estimated at USD 247.8 million in 2022 and is anticipated to reach USD 318.5 million by 2031, expanding at a CAGR of 2.9% during the forecast period.

Mitomycin C is an antibiotic chemotherapeutic agent isolated from Streptomyces caespitosus that inhibits DNA synthesis. It is approved for use in combination with other approved chemotherapeutic agents in the treatment of disseminated adenocarcinoma of the stomach or pancreas, as well as in the treatment of other solid tumors, including breast cancer and non-small cell lung cancer (NSCLC).

Mitomycin C is used as an antineoplastic agent and for slowing of fibroblast formation in open-angle glaucoma. Mitomycin for Injection is a sterile dry mixture of mitomycin and mannitol, which, when reconstituted with Sterile Water for Injection, provides a solution for intravenous administration. Each vial contains either mitomycin 5 mg and mannitol 10 mg, mitomycin 20 mg and mannitol 40 mg, mitomycin 40 mg and mannitol 80 mg.

Macro-economic Factors

Rising GDPs of Emerging Economies

The emerging market economy refers to a country that is in the process of development. Countries such as Brazil, Russia, India, China (BRIC), and others in Latin America and Southeast Asia are key developing economies.

The economic growth of emerging countries is growing by 6% to 7% annually, whereas countries with an already well-established economy report growth rate below 3%. Therefore, the GDP growth rates for emerging economies are outperforming those of developed countries.

In 2021, the total contribution of the healthcare industry to global GDP was 10%. Thus, the rising GDP of emerging economies plays a crucial role in boosting the market.

Coronavirus

The outbreak of the coronavirus pandemic impeded the growth of the market in various countries, including the US, China, Germany, Japan, and India. In 2020, the global GDP was about USD 84.68 trillion and it declined by 3.4%, while the volume of world trade was reduced by 5.3%, and foreign direct investment (FDI) flows decreased by 35% as compared to the previous year. The pandemic has restricted the growth of the global mitomycin C market, owing to severe disruptions in businesses and the supply chain.

Manufacturers of mitomycin C were negatively affected during the pandemic, due to restrictions and the closure of global industries. The closure of many manufacturing plants and distributor companies during the COVID-19 crisis affected the mitomycin C market.

According to World Health Organization (WHO) during the pandemic, people living with cancer, and other non-communicable diseases (NCDs) experienced difficulties in accessing routine medicines.

Supply chain issues caused by the COVID-19 pandemic, as well as the care needs of patients with COVID-19, have led to shortages of drugs and other products used in cancer care. The increasing need for COVID-19 therapies and supportive care drugs had led to shortages that impacted oncology drug manufacturing.

Market Dynamics

Market Driver- Increasing Prevalence of Cancers

Cancer is a major public health problem globally, and it is the second leading cause of death in the US. It accounts for approximately 10 million deaths in 2020, which is nearly one in every six deaths. Around 400,000 children are diagnosed with cancer every year. Breast cancer is the most commonly occurring cancer in women and the most common cancer overall. In 2020, around 2.3 million women were diagnosed with breast cancer, and breast cancer accounted for 685,000 deaths globally.

Bladder cancer is the 6th most common cancer in men. According to the American Cancer Society (ACS), 81,180 new cases of bladder cancer in the US constituted around 4.2% of all new cancer cases in 2022. Over one million cases of gastric cancer are diagnosed each year around the world. The cumulative risk of developing gastric cancer from birth to age 74 is 1.87% in males and 0.79% in females globally. Thus, the rising prevalence of cancer is expected to drive the mitomycin C market during the forecast period.

Market Driver- Rising Application of Mitomycin C in Ophthalmology Surgery

Trabeculectomy, also called as filtration surgery, is a surgical procedure used in the treatment of glaucoma to lower intraocular pressure. Trabeculectomy is performed as a treatment for many types of glaucoma.

Mitomycin C is applied between the sclera and conjunctiva during the initial stages of a trabeculectomy to prevent excessive post-operative scarring and fibrosis. It reduces the risk of surgical failure. Its use and application in ophthalmology have been increasing in recent years, due to its modulatory effects on wound healing.

Current applications of mitomycin C include pterygium surgery, glaucoma surgery, corneal refractive surgery, cicatricial eye disease, conjunctival neoplasia, and allergic eye disease. Increasing use of mitomycin C in ophthalmology surgery is expected to drive the market in the coming years, as it is effective in trabeculectomy surgery.

Market Restraint- Availability of Substitutes

Some of the common substitutes for mitomycin C includes cisplatin, epirubicin, gemcitabine, and doxorubicin. Epirubicin is used to treat breast cancer, whereas cisplatin injection is used to treat advanced cancer of the bladder, ovaries, or testicles. Doxorubicin is considered one of the strongest chemotherapy drugs for breast cancer.

Intravesical Bacilli Calmette-Guerin (BCG) is used as the first-line therapy for many patients with high-risk non-muscle invasive bladder cancer. It has been proven to reduce and delay tumor progression. It acts as an alternative to mitomycin C, as it is more effective than mitomycin C for the prevention of bladder cancer recurrence.

Dexamethasone nanoparticles (DexNP) are potent anti-inflammatory and anti-fibroblast agents that offer an alternative to mitomycin C in glaucoma surgery. DexNP eye drops are an effective postoperative trabeculectomy treatment. Thus, the availability of substitutes such as cisplatin, epirubicin, gemcitabine, and doxorubicin is expected to restrain the market in the coming years.

Market Opportunity- Rising Governmental Spending & R&D Activities

Governments across the globe are investing in the oncology sector to increase per capita healthcare spending. The oncology industry is an essential component of the healthcare industry. Healthcare expenditure plays an important role in providing opportunities for maintaining health.

It strengthens human capital and improves productivity, thereby contributing to economic performance. In 2022, global oncology spending totaled USD 193 Bn, with a rapid annual growth trend. Increasing investments from key market players in R&D activities and rising focus on product innovations are creating opportunities for oncology manufacturing companies across the globe.

Scope of the Report

The report on the Global Mitomycin C Market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Mitomycin C Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	By Type (2mg, 10 mg, 40 mg, and Others), By Application (Cancer Treatment, Ophthalmic Use, and Others)
Regional Scope	Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered	UroGen Pharma, Inc, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Viatris Inc., Taj Pharma, Laboratorio Varifarma S.A, Accord Healthcare, Inc., Mobius Therapeutics, LLC, Laboratorios Aspen S.A., Meitheal Pharmaceuticals.

Segmental Outlook

Based on type, the market is segmented into the 2mg, 10 mg, 40 mg, and others. The 40mg segment is anticipated to expand at a significant CAGR during the forecast period, as it is widely used in bladder cancer treatment. The 10 mg segment is expected to hold a substantial share of the market during the forecast period, as it relieves the symptoms of pancreatic cancer, such as weight loss.

Based on the application, the market is bifurcated into cancer treatment, ophthalmic use, and others. The cancer treatment segment is projected to register a remarkable CAGR during the forecast period, as mitomycin C is an effective antitumor agent in breast cancer. The ophthalmic use segment is expected to grow at a rapid pace in coming years, as mitomycin C is used as a fibroblast proliferation inhibitor during surgery to reduce the chance of recurrence of the pterygium.

Regional Outlook

Based on regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in the North America is projected to expand at a significant CAGR during the forecast period owing to the increasing investment in cancer research in the region.

The market in the Asia Pacific is expected to hold significant market share during the forecast period, as Japan becoming the most prominent supplier of this drug across the world. The manufacturing of mitomycin is rising substantially in India, aiding the Asia Pacific mitomycin market. Leading manufacturers are focusing actively on expanding their bases in the region, which is projected to increase its prominence in the global market.

Key Benefits for Industry Participants & Stakeholders

In-depth Analysis of the Global Mitomycin C Market
Historical, Current, and Projected Market Size in terms of Value
Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
Industry Drivers, Restraints, and Opportunities Covered in the Study
Recent Industry Trends and Developments
Competitive Landscape & Strategies of Key Players
Neutral Perspective on Global Mitomycin C Market Performance

Segments

By Type

2mg
10 mg
40 mg
Others

By Application

Cancer Treatment
Ophthalmic Use
Others

By Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Key Market Players Profiled in the Report

UroGen Pharma, Inc
Teva Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals PLC
Viatris Inc.
Taj Pharma
Laboratorio Varifarma S.A
Accord Healthcare, Inc.
Mobius Therapeutics, LLC
Laboratorios Aspen S.A.
Meitheal Pharmaceuticals

Competitive Landscape

Manufacturers operating in the Global Mitomycin C Market includes UroGen Pharma, Inc, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Viatris Inc., Taj Pharma, Laboratorio Varifarma S.A, Accord Healthcare, Inc., Mobius Therapeutics, LLC, Laboratorios Aspen S.A., Meitheal Pharmaceuticals. Market Players are pursuing key strategies such as acquisitions, collaborations, and geographic expansion where a potential opportunity arises for the Global Mitomycin C Market.

Table Of Content

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mitomycin C Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Mitomycin C Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Mitomycin C Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Mitomycin C Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Mitomycin C Market Size & Forecast, 2016-2031
      4.5.1 Mitomycin C Market Size and Y-o-Y Growth
      4.5.2 Mitomycin C Market Absolute $ Opportunity
Chapter 5 Global Mitomycin C Market Analysis and Forecast By Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Type
      5.1.2 Basis Point Share (BPS) Analysis By Type
      5.1.3 Absolute $ Opportunity Assessment By Type
   5.2 Mitomycin C Market Size Forecast By Type
      5.2.1 2 Mg
      5.2.2 10 Mg
      5.2.3 40 Mg
      5.2.4 Others
   5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Mitomycin C Market Analysis and Forecast By Application
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Application
      6.1.2 Basis Point Share (BPS) Analysis By Application
      6.1.3 Absolute $ Opportunity Assessment By Application
   6.2 Mitomycin C Market Size Forecast By Application
      6.2.1 Cancer Treatment
      6.2.2 Ophthalmic Use
      6.2.3 Others
   6.3 Market Attractiveness Analysis By Application
Chapter 7 Global Mitomycin C Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Mitomycin C Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
   8.1 Introduction
   8.2 Current & Future Impact Analysis
   8.3 Economic Impact Analysis
   8.4 Government Policies
   8.5 Investment Scenario
Chapter 9 North America Mitomycin C Analysis and Forecast
   9.1 Introduction
   9.2 North America Mitomycin C Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Mitomycin C Market Size Forecast By Type
      9.6.1 2 Mg
      9.6.2 10 Mg
      9.6.3 40 Mg
      9.6.4 Others
   9.7 Basis Point Share (BPS) Analysis By Type
   9.8 Absolute $ Opportunity Assessment By Type
   9.9 Market Attractiveness Analysis By Type
   9.10 North America Mitomycin C Market Size Forecast By Application
      9.10.1 Cancer Treatment
      9.10.2 Ophthalmic Use
      9.10.3 Others
   9.11 Basis Point Share (BPS) Analysis By Application
   9.12 Absolute $ Opportunity Assessment By Application
   9.13 Market Attractiveness Analysis By Application
Chapter 10 Europe Mitomycin C Analysis and Forecast
   10.1 Introduction
   10.2 Europe Mitomycin C Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Mitomycin C Market Size Forecast By Type
      10.6.1 2 Mg
      10.6.2 10 Mg
      10.6.3 40 Mg
      10.6.4 Others
   10.7 Basis Point Share (BPS) Analysis By Type
   10.8 Absolute $ Opportunity Assessment By Type
   10.9 Market Attractiveness Analysis By Type
   10.10 Europe Mitomycin C Market Size Forecast By Application
      10.10.1 Cancer Treatment
      10.10.2 Ophthalmic Use
      10.10.3 Others
   10.11 Basis Point Share (BPS) Analysis By Application
   10.12 Absolute $ Opportunity Assessment By Application
   10.13 Market Attractiveness Analysis By Application
Chapter 11 Asia Pacific Mitomycin C Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Mitomycin C Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Mitomycin C Market Size Forecast By Type
      11.6.1 2 Mg
      11.6.2 10 Mg
    11.6.3 40 Mg
      11.6.4 Others
   11.7 Basis Point Share (BPS) Analysis By Type
   11.8 Absolute $ Opportunity Assessment By Type
   11.9 Market Attractiveness Analysis By Type
   11.10 Asia Pacific Mitomycin C Market Size Forecast By Application
      11.10.1 Cancer Treatment
      11.10.2 Ophthalmic Use
      11.10.3 Others
   11.11 Basis Point Share (BPS) Analysis By Application
   11.12 Absolute $ Opportunity Assessment By Application
   11.13 Market Attractiveness Analysis By Application
Chapter 12 Latin America Mitomycin C Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Mitomycin C Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Mitomycin C Market Size Forecast By Type
      12.6.1 2 Mg
      12.6.2 10 Mg
      12.6.3 40 Mg
      12.6.4 Others
   12.7 Basis Point Share (BPS) Analysis By Type
   12.8 Absolute $ Opportunity Assessment By Type
   12.9 Market Attractiveness Analysis By Type
   12.10 Latin America Mitomycin C Market Size Forecast By Application
      12.10.1 Cancer Treatment
      12.10.2 Ophthalmic Use
      12.10.3 Others
   12.11 Basis Point Share (BPS) Analysis By Application
   12.12 Absolute $ Opportunity Assessment By Application
   12.13 Market Attractiveness Analysis By Application
Chapter 13 Middle East & Africa (MEA) Mitomycin C Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Mitomycin C Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Mitomycin C Market Size Forecast By Type
      13.6.1 2 Mg
      13.6.2 10 Mg
      13.6.3 40 Mg
      13.6.4 Others
   13.7 Basis Point Share (BPS) Analysis By Type
   13.8 Absolute $ Opportunity Assessment By Type
   13.9 Market Attractiveness Analysis By Type
   13.10 Middle East & Africa (MEA) Mitomycin C Market Size Forecast By Application
      13.10.1 Cancer Treatment
      13.10.2 Ophthalmic Use
      13.10.3 Others
   13.11 Basis Point Share (BPS) Analysis By Application
   13.12 Absolute $ Opportunity Assessment By Application
   13.13 Market Attractiveness Analysis By Application
Chapter 14 Competition Landscape
   14.1 Mitomycin C Market: Competitive Dashboard
   14.2 Global Mitomycin C Market: Market Share Analysis, 2022
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      14.3.1 UroGen Pharma, Inc
      14.3.2 Teva Pharmaceutical Industries Ltd.
      14.3.3 Hikma Pharmaceuticals PLC
      14.3.4 Viatris Inc.
      14.3.5 Taj Pharma
      14.3.6 Laboratorio Varifarma S.A
      14.3.7 Accord Healthcare, Inc.
      14.3.8 Mobius Therapeutics, LLC
      14.3.9 Laboratorios Aspen S.A.
      14.3.10 Meitheal Pharmaceuticals

Methodology

Purchase Premium Report

Buy Now

Request For Sample

Request For Customization

Enquiry Before Buying

Speak With Analyst

Customize This Report

Ask for Research To Be Focused On Specific Regions or Segments
Receive Data As Per Your Format and Definition
Companies Profiled based on Your Requirements
Breaking Down Competitive Landscape as per Your Requirements
Any Level of Customization

Our Clients

Client Testinomials

We needed a highly accurate and precise report, which Growth Market Reports delivered promptly. The company compiled information from a wide array of reliable agencies and sourcess.It is extremely satisfactory to be working with you.
Strategy Head of Major Tech Company

We were very pleased to contact Growth Market Reports as they tailored reports precisely as per our requirements. As we are dealing with the aerospace and defense industry, we need reports of high accuracy and substantial quality.
Major Player in Defense Industry

Extremely delighted to have a well-crafted report on “Global Packaging Solutions Market Research Report” from your team. Thank you for providing me with all our requirements and for incorporating our suggestions.
CMO of Leading Packaging Company from USA

I had a good experience working with Growth Market Reports as they were very open to all constructive changes in the report. I found that the report had its charm embedded with ample of data.
Founder and Managing Partner of Major Korean Company

Our company has been working with Growth Market Reports for some years now and we are very happy with the quality of the reports provided by the company.I, on behalf of my organization, would like to thank you for offering professional reports.
Global Consulting Firm

Quick Contact

+1 909 414 1393

sales@growthmarketreports.com

Growth Market Report

Certified By